Drugs / ORX142
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07082829 | Jun 2025 → Jun 2026 overdue | hypersomnia | Centessa Pharmaceuticals (UK) Limited | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-07-04 | Nxera Pharma UK Limited | Nxera to Receive US$4.8 mn in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel OX2R Agonist nxera.life ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORX142 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07082829 ↗ |